Enterprise Value
568.3M
Cash
87.35M
Avg Qtr Burn
-10.3M
Short % of Float
7.93%
Insider Ownership
2.69%
Institutional Own.
41.94%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Gvoke® Details Diabetes | Approved Quarterly sales | |
Recorlev® (levoketoconazole) Details Rare diseases, Cushing’s syndrome | Approved Quarterly sales | |
Keveyis® (dichlorphenamide) Details Rare diseases | Approved Quarterly sales | |
XeriSol® (Levothyroxine) (XP-8121) Details Adult hypoparathyroidism | Phase 2 Update | |
Failed Discontinued | ||
Gvoke RTU Micro™ Details Hypoglycemia, Type 1 diabetes, Type 2 diabetes | Failed Discontinued | |
Pramlintide-Insulin Details Type 1 diabetes, Diabetes, Type 2 diabetes | Failed Discontinued |